157 related articles for article (PubMed ID: 38635732)
1. Visual outcomes of intraocular inflammation after brolucizumab injection in Japanese patients with neovascular age-related macular degeneration.
Hirono K; Maruyama-Inoue M; Yanagi Y; Kadonosono K
PLoS One; 2024; 19(4):e0302295. PubMed ID: 38635732
[TBL] [Abstract][Full Text] [Related]
2. Clinical features and associated factors of intraocular inflammation following intravitreal brolucizumab as switching therapy for neovascular age-related macular degeneration.
Sotani R; Matsumiya W; Kim KW; Miki A; Yasuda E; Maeda Y; Hara R; Kusuhara S; Nakamura M
Graefes Arch Clin Exp Ophthalmol; 2023 Aug; 261(8):2359-2366. PubMed ID: 36971800
[TBL] [Abstract][Full Text] [Related]
3. Comparison of functional and morphologic changes between brolucizumab and faricimab in neovascular age-related macular degeneration.
Maruyama-Inoue M; Yanagi Y; Inoue T; Kadonosono K
Graefes Arch Clin Exp Ophthalmol; 2024 Feb; 262(2):589-599. PubMed ID: 37750953
[TBL] [Abstract][Full Text] [Related]
4. Short-term outcomes of switching to brolucizumab in japanese patients with neovascular age-related macular degeneration.
Kitajima Y; Maruyama-Inoue M; Ikeda S; Ito A; Inoue T; Yanagi Y; Kadonosono K
Jpn J Ophthalmol; 2022 Nov; 66(6):511-517. PubMed ID: 36149566
[TBL] [Abstract][Full Text] [Related]
5. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
Monés J; Srivastava SK; Jaffe GJ; Tadayoni R; Albini TA; Kaiser PK; Holz FG; Korobelnik JF; Kim IK; Pruente C; Murray TG; Heier JS
Ophthalmology; 2021 Jul; 128(7):1050-1059. PubMed ID: 33207259
[TBL] [Abstract][Full Text] [Related]
6. Baseline characteristics associated with the incidence of intraocular inflammation after the intravitreous injection of brolucizumab.
Hoshi K; Kunikata H; Aizawa N; Yasuda M; Okabe T; Takizawa H; Abe T; Nakazawa T
Int Ophthalmol; 2023 Dec; 43(12):4701-4709. PubMed ID: 38044420
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal Aflibercept versus Brolucizumab for Treatment-Naive Neovascular Age-Related Macular Degeneration with Type 1 Macular Neovascularization: Comparison of Short-Term Outcomes.
Hoshino J; Matsumoto H; Mukai R; Nakamura K; Akiyama H
Ophthalmologica; 2022; 245(5):413-420. PubMed ID: 35834995
[TBL] [Abstract][Full Text] [Related]
8. Clinical Characteristics and Outcomes of Eyes with Intraocular Inflammation after Brolucizumab: Post Hoc Analysis of HAWK and HARRIER.
Singer M; Albini TA; Seres A; Baumal CR; Parikh S; Gale R; Kaiser PK; Lobach I; Feltgen N; Joshi MR; Ziemssen F; Bodaghi B
Ophthalmol Retina; 2022 Feb; 6(2):97-108. PubMed ID: 33971353
[TBL] [Abstract][Full Text] [Related]
9. One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.
Matsumoto H; Hoshino J; Mukai R; Nakamura K; Akiyama H
Sci Rep; 2022 May; 12(1):8195. PubMed ID: 35581196
[TBL] [Abstract][Full Text] [Related]
10. Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration.
Ota H; Takeuchi J; Nakano Y; Horiguchi E; Taki Y; Ito Y; Terasaki H; Nishiguchi KM; Kataoka K
Jpn J Ophthalmol; 2022 May; 66(3):278-284. PubMed ID: 35233693
[TBL] [Abstract][Full Text] [Related]
11. Intraocular Inflammation Secondary to Intravitreal Brolucizumab Injection for Neovascular Age-Related Macular Degeneration in a Patient with Cognitive Impairment.
Ueji N; Mase Y; Kubo A; Matsubara H; Chujo S; Matsui Y; Kondo M
Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893574
[No Abstract] [Full Text] [Related]
12. Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map.
Khanani AM; Zarbin MA; Barakat MR; Albini TA; Kaiser PK; B G; Agashivala N; Yu JS; Wykoff CC; MacCumber MW
JAMA Ophthalmol; 2022 Jan; 140(1):20-28. PubMed ID: 34817566
[TBL] [Abstract][Full Text] [Related]
13. Short-Term Safety and Efficacy of Intravitreal Brolucizumab Injections for Neovascular Age-Related Macular Degeneration: A Multicenter Retrospective Real-World Study.
Kim DJ; Jin KW; Han JM; Lee SH; Park YS; Lee JY; Lee EK; Lee JS; Kim ST; Shin MH; Lee CS; Jung HH; Jang JY; Kim M; Kim YH; Kim JH; Park KH; Park SJ; Joo K; Ji YS; Sagong M; Woo SJ
Ophthalmologica; 2023; 246(3-4):192-202. PubMed ID: 36720210
[TBL] [Abstract][Full Text] [Related]
14. INTRAOCULAR INFLAMMATION INCIDENCE AFTER INTRAVITREAL BROLUCIZUMAB INJECTION FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
Pakravan P; Patel V; Lai J; Shaheen A; Kalahasty K; Reyes-Capo DP; Chau V; Rosenfeld PJ; Haddock LJ; Schwartz SG; Smiddy WE; Kovach JL; Sridhar J; Flynn HW; Albini TA; Yannuzzi NA
Retina; 2023 Oct; 43(10):1717-1722. PubMed ID: 37320859
[TBL] [Abstract][Full Text] [Related]
15. Detection and Management of Intraocular Inflammation after Brolucizumab Treatment for Neovascular Age-Related Macular Degeneration.
Bodaghi B; Souied EH; Tadayoni R; Weber M; Ponthieux A; Kodjikian L
Ophthalmol Retina; 2023 Oct; 7(10):879-891. PubMed ID: 37343623
[TBL] [Abstract][Full Text] [Related]
16. Retinal arterial occlusive vasculitis after multiple intravitreal brolucizumab injections for diabetic macular edema.
Hirano T; Toriyama Y; Takahashi Y; Hoshiyama K; Murata T
Am J Ophthalmol Case Rep; 2023 Mar; 29():101788. PubMed ID: 36632338
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration.
Mukai R; Matsumoto H; Akiyama H
PLoS One; 2021; 16(12):e0259879. PubMed ID: 34871313
[TBL] [Abstract][Full Text] [Related]
18. The combination therapy of subtenon triamcinolone acetonide injection and intravitreal brolucizumab for brolucizumab-related intraocular inflammation.
Shigemoto Y; Sakurada Y; Fukuda Y; Matsubara M; Parikh R; Kashiwagi K
Medicine (Baltimore); 2021 Oct; 100(42):e27580. PubMed ID: 34678906
[TBL] [Abstract][Full Text] [Related]
19. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
Khanani AM; Brown DM; Jaffe GJ; Wykoff CC; Adiguzel E; Wong R; Meng X; Heier JS;
Ophthalmology; 2022 Sep; 129(9):974-985. PubMed ID: 35537533
[TBL] [Abstract][Full Text] [Related]
20. Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab.
Baumal CR; Spaide RF; Vajzovic L; Freund KB; Walter SD; John V; Rich R; Chaudhry N; Lakhanpal RR; Oellers PR; Leveque TK; Rutledge BK; Chittum M; Bacci T; Enriquez AB; Sund NJ; Subong ENP; Albini TA
Ophthalmology; 2020 Oct; 127(10):1345-1359. PubMed ID: 32344075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
